Article
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Neuro-oncology - 1 Dec 2011
Grommes Christian, Oxnard Geoffrey R, Kris Mark G, Miller Vincent A, Pao William, Holodny Andrei I, Clarke Jennifer L, Lassman Andrew B
Abstract excerpt
Erlotinib is effective for epidermal growth factor receptor (EGFR) mutant lung cancer, but CNS penetration at standard daily dosing is limited. We previously reported that intermittent "pulsatile" administration of high-dose (1500 mg) erlotinib once weekly was tolerable and achieved concentrations in cerebrospinal fluid exceeding the half maximal inhibitory concentration for EGFR mutant lung cancer cells in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.